Nippon Zenyaku Kogyo Co., Ltd.

Animal Allergy Clinical Laboratories Inc.

Osaka University

Riken Corporation

Kazusa Dna Research Institute

Toshihiro Tsukui

Hajime Tsujimoto

Shigehiro Iwabuchi

Ken Ishii

Kenichi Masuda

Osamu Ohara

Shizuo Akira

Yasuyuki Ishii

Takahiro Nagase

Cevayir Coban

Masahiro Kato

Yoshihiro Yamaguchi

Rieko Suzuki

Reiko Ohara

Miyuki Kageyama

Yoshikatsu Igari

Keiichi Ohata

Provided are an anti-canine TARC antibody for use in the treatment and diagnosis of canine atopic dermatitis, and a method for treating or diagnosing canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 4, or a functional fragment thereof binding to canine TARC.

Anti-canine TARC antibody used for treatment and diagnosis of canine atopic dermatitis

The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide having a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent having the peptides; and a method for producing the peptide.

Multiplexed same type-antigenic peptide

Problem to be Solved: The present invention is intended to provide a polynucleotide encoding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. Solution: The present invention is DNA encoding a heavy-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 2 or 6 and DNA encoding a light-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 4 or 8, and an anti-dog IgE monoclonal antibody which binds to dog IgE, containing these variable regions or a functional fragment thereof which binds to dog IgE.

Anti-dog IgE monoclonal antibody, and light-chain variable region and heavy-chain variable region of anti-dog IgE monoclonal antibody

It is intended to provide an IgE peptide vaccine that can be used in the prevention or treatment of allergic diseases in animals other than mice, such as humans or dogs. The present invention provides a peptide consisting of (i) the amino acid sequence represented by SEQ ID NO: 28, or (ii) an amino acid sequence consisting of at least 10 consecutive amino acids in the amino acid sequence represented by SEQ ID NO: 28, wherein the peptide, when administered to an animal, is capable of specifically binding to a CH3 region in an IgE antibody of the animal and thereby blocking the binding of the IgE antibody to an IgE receptor.

IgE peptide vaccine

The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or &#x3b2;-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine.

Adjuvant

A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided:

Mite allergen

Growing community of inventors

Koriyama, Japan

Toshihiro Tsukui